The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Amines
/ administration & dosage
Analysis of Variance
Animals
Antiprotozoal Agents
/ administration & dosage
Female
Leishmania major
/ drug effects
Leishmaniasis, Cutaneous
/ drug therapy
Liposomes
Meglumine Antimoniate
/ administration & dosage
Mice
Mice, Inbred BALB C
Rabbits
Spleen
/ parasitology
Amastigotes
Cutaneous leishmaniasis
Liposome
Meglumine antimoniate
Promastigotes
Steraylamine
Journal
Experimental parasitology
ISSN: 1090-2449
Titre abrégé: Exp Parasitol
Pays: United States
ID NLM: 0370713
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
18
10
2018
revised:
03
03
2019
accepted:
17
03
2019
pubmed:
23
3
2019
medline:
15
5
2019
entrez:
23
3
2019
Statut:
ppublish
Résumé
Topical treatment of cutaneous leishmaniasis has demonstrated appropriate alternative for reducing toxicity of conventional treatments, improving patients' compliance and reducing treatment costs. Furthermore, outbreak of cutaneous leishmaniasis in war and conflict zones emerges finding an effective, economical and user-friendly treatment. In the context of liposomal topical drug delivery, we developed and characterized meglumine antimoniate (MA) loaded liposomes and investigated their effectiveness in topical treatment of cutaneous leishmaniasis. Previously, we showed the promising use of liposomal formulation of MA in treatment of cutaneous leishmaniasis in BALB/c mice. Here, we included Stearylamine (SA) in liposomes' structure which has antileishmanial activity by itself. . Size and encapsulation efficiency of liposomes were measured and in vitro permeation was performed using mice model. In vitro toxicity of liposomes was measured against leishmania promastigotes and amastigotes. Liposomes were used topically twice a day for 4 weeks to treat leishmania lesions in BALB\c mice model. In vitro permeation study showed liposomal formulations improved the percent of MA permeation compared with MA-cream. Promastigotes and amastigotes assay results showed significant enhanced toxicity in Liposomal-MA containing SA compared to Lip-MA. In BALB\c mice model of cutaneous leishmaniasis, liposomal groups exhibited significantly smaller lesion size compared to control groups (p < 0.01). In addition, the spleen parasite burden was significantly (P < 0.01) lower in mice treated with selected liposomal MA than in mice treated with PBS, control liposomes and MA cream. The results of this study showed that SA-liposomes encapsulated with MA might be useful as a candidate for the topical treatment of CL which merit further investigation.
Identifiants
pubmed: 30898544
pii: S0014-4894(18)30469-7
doi: 10.1016/j.exppara.2019.03.004
pii:
doi:
Substances chimiques
Amines
0
Antiprotozoal Agents
0
Liposomes
0
Meglumine Antimoniate
75G4TW236W
stearylamine
FFV58UNY7O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-35Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.